WSJ: Teva close to CEO choice, with acting CEO and ex-Actavis chief still up for the job

Teva Pharmaceutical Industries ($TEVA) is said to be close to choosing Israeli executive Erez Vigodman to take its empty CEO chair, but as the Wall Street Journal reports, some other candidates are still in the running. Acting CEO Eyal Desheh is one of them, as is former Actavis ($ACT) CEO Claudio Albrecht, who stepped out of that company after its merger with Watson Laboratories. Report (sub. req.)

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.